Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci120 in healthy volunteers
NCT06827457Phase 1Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Nov 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autoimmune disease comparing GenSci120 with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at 113 days, Serious Adverse Events at 113 days and 11 more. Started Feb 2025; status: completed.
02
Drugs
GenSci120
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT06827457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827457.